Nanosphere, Inc.  

(Public, NASDAQ:NSPH)   Watch this stock  
Find more results for NSPH
+0.008 (3.47%)
Real-time:   10:15AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.22 - 0.24
52 week 0.22 - 2.28
Open 0.23
Vol / Avg. 300,883.00/3.60M
Mkt cap 27.62M
P/E     -
Div/yield     -
EPS -0.48
Shares 117.30M
Beta 3.55
Inst. own 27%
May 5, 2015
Q1 2015 Nanosphere Inc Earnings Release (Estimated) Add to calendar
Feb 11, 2015
Q4 2014 Nanosphere Inc Earnings Call - Webcast
Jan 28, 2015
Nanosphere Inc Announces Fourth Quarter and Full Year 2014 Preliminary Top Line Results - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -203.40% -273.41%
Operating margin -196.66% -263.75%
EBITD margin - -250.68%
Return on average assets -99.33% -76.76%
Return on average equity -174.39% -111.93%
Employees 169 -
CDP Score - -


4088 Commercial Avenue
United States - Map
+1-847-4009000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Nanosphere, Inc. is engaged in providing targeted molecular diagnostic tests that can lead to earlier disease detection, optimal patient treatment and improved healthcare economics. It also conducts tests for the development of medicines. The Company�s platform, the Verigene System, enables clinicians to rapidly identify and treat the bacteria and viruses responsible for some of the most complex, costly and deadly infectious diseases. The Verigene System includes a bench-top molecular diagnostics workstation that is an advanced platform for genomic and protein testing. The Verigene System comprises a microfluidics processor, a touchscreen reader and disposable test cartridges. The Company is focused on the infectious disease diagnostics market.

Officers and directors

Michael K. McGarrity President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Ann Wallin Interim Chief Financial Officer, Chief Accounting Officer
Bio & Compensation  - Reuters
Kenneth Bahk Ph.D. Chief Strategy Officer
Age: 40
Bio & Compensation  - Reuters
Kristopher A. Wood Director
Bio & Compensation  - Reuters
Gene S Cartwright Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Andre de Bruin Independent Director
Age: 67
Bio & Compensation  - Reuters
Erik Holmlin Ph.D. Independent Director
Age: 46
Bio & Compensation  - Reuters
Lorin Jeffry Randall Independent Director
Age: 70
Bio & Compensation  - Reuters